Pancreatic Cancer Research

ResearcherTohoku UniversityNo recent work listed

Takanori Morikawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2014-651X; OpenAlex author ID A5043003874. Sources: OpenAlex.

Their work

Papers
29 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 4 papers · 2018: none · 2019: none · 2020: 4 papers · 2021: 8 papers · 2022: 3 papers · 2023: 5 papers

Papers 29

  1. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical … Co-author DOI 10.1002/jhbp.1282↗
  2. GATA6 and CK5 Stratify the Survival of Patients With Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1016/j.modpat.2023.100102↗
  3. Negative prognostic impact of sarcopenia before and after neoadjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1016/j.pan.2022.11.010↗
  4. Reduced expression of phosphorylated ataxia-telangiectasia mutated gene is related to poor prognosis and gemcitabine chemoresistance in pancreatic cancer. Co-author DOI 10.1186/s12885-023-11294-3↗
  5. [A Case of an Elderly Patient Who Underwent Conversion Resection for Pancreatic Cancer with Positive Peritoneal Cytology]. Co-author PMID 36807179↗
  6. Levels of tumor markers CEA/CA 19-9 in serum and peritoneal lavage predict postoperative recurrence in patients with pancreatic cancer. Co-author DOI 10.1002/ags3.12597↗
  7. What is the impact of zinc deficiency for pancreatectomies in patients with pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.pan.2021.12.006↗
  8. Impact of Tumor-Derived DNA Testing in Peritoneal Lavage of Pancreatic Cancer Patients with and Without Occult Intra-Abdominal Metastases. Co-author DOI 10.1245/s10434-021-10997-w↗
  9. Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese… Co-author DOI 10.1002/ags3.12482↗
  10. Circulating tumor DNA as a predictive marker for occult metastases in pancreatic cancer patients with radiographically non-metastatic disease. Co-author DOI 10.1002/jhbp.993↗
  11. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. First author DOI 10.1007/s00595-020-02121-4↗
  12. Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery fo… Co-author DOI 10.1007/s00595-021-02279-5↗
  13. Silencing of LRRFIP1 enhances the sensitivity of gemcitabine in pancreatic cancer cells by activating JNK/c-Jun signaling. Co-author DOI 10.1016/j.pan.2021.02.018↗
  14. MicroRNA-593-3p Expression in Peritoneal Lavage Fluid as a Prognostic Marker for Pancreatic Cancer Patients Undergoing Staging Laparoscopy. Co-author DOI 10.1245/s10434-020-09440-3↗
  15. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up… Co-author DOI 10.1245/s10434-021-09718-0↗
  16. Stomatin‑like protein 2 induces metastasis by regulating the expression of a rate‑limiting enzyme of the hexosamine biosynthetic pathway in pancreatic cancer. Co-author DOI 10.3892/or.2021.8041↗
  17. Prognostic indicators in pancreatic cancer patients undergoing total pancreatectomy. Co-author DOI 10.1007/s00595-019-01924-4↗
  18. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.08.022↗
  19. Stromal expression of hemopexin is associated with lymph-node metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0235904↗
  20. [A Case of Initially Locally Advanced Pancreatic Cancer Curatively Resected after Carbon-Ion Radiotherapy with Gemcitabine]. Co-author PMID 33468929↗
  21. Predictive risk factors for peritoneal recurrence after pancreatic cancer resection and strategies for its prevention. Co-author DOI 10.1007/s00595-017-1531-9↗
  22. Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed … Co-author DOI 10.1186/s40792-017-0290-6↗
  23. A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver m… Co-author DOI 10.1186/s40792-017-0409-9↗
  24. [Multidisciplinary Therapy with Gemcitabine and Nab-Paclitaxel for Unresectable Pancreatic Cancer]. Co-author PMID 29394594↗
  25. [A Case of Successful Stomach-Preserving Pancreaticoduodenectomy with Celiac Artery Resection after Neoadjuvant Chemoradiation Therapy for Pancreatic Cancer wi… Co-author PMID 28133191↗
  26. [Laparoscopic surgery for pancreatic cancer]. Co-author PMID 25857001↗
  27. [A case of pancreatic cancer with local recurrence and liver metastases eight years after surgery]. Co-author PMID 25731467↗
  28. [A case of successful R0 resection after neoadjuvant therapy for locally advanced unresectable pancreatic cancer]. Co-author PMID 24393949↗
  29. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Co-author DOI 10.1007/s10147-011-0220-8↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michiaki Unno · 29 shared papers, 2011–2023 · strength 3.05
  2. Kei Nakagawa · 27 shared papers, 2013–2023 · strength 2.94
  3. Masamichi Mizuma · 27 shared papers, 2013–2023 · strength 2.94
  4. Fuyuhiko Motoi · 22 shared papers, 2011–2023 · strength 2.11
  5. Tatsuo Hata · 10 shared papers, 2017–2023 · strength 1.22
  6. Tatsuyuki Takadate · 13 shared papers, 2011–2022 · strength 1.08
  7. Shuichi Aoki · 9 shared papers, 2013–2023 · strength 1.06
  8. Kyohei Ariake · 11 shared papers, 2017–2023 · strength 1.02
  9. Masahiro Iseki · 8 shared papers, 2017–2023 · strength 0.93
  10. Shimpei Maeda · 11 shared papers, 2011–2021 · strength 0.90
  11. Kei Kawaguchi · 6 shared papers, 2014–2022 · strength 0.60
  12. Toru Furukawa · 4 shared papers, 2021–2023 · strength 0.59
  13. Daisuke Douchi · 4 shared papers, 2021–2023 · strength 0.58
  14. Kazuharu Chiba · 3 shared papers, 2021–2022 · strength 0.42
  15. Koetsu Inoue · 2 shared papers, 2023 · strength 0.30
  16. Mitsuhiro Shimura · 3 shared papers, 2017–2023 · strength 0.29
  17. Takashi Kokumai · 2 shared papers, 2021–2023 · strength 0.28
  18. Shinichi Egawa · 5 shared papers, 2011–2017 · strength 0.20
  19. Jingyu Xun · 1 shared paper, 2023 · strength 0.16
  20. Katsuya Hirose · 1 shared paper, 2023 · strength 0.16
  21. Naohiro Hirano · 1 shared paper, 2023 · strength 0.15
  22. Shin Miura · 1 shared paper, 2023 · strength 0.15
  23. Yuko Omori · 1 shared paper, 2023 · strength 0.15
  24. Atsushi Masamune · 1 shared paper, 2023 · strength 0.15
  25. Yusuke Mizukami · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.